FMP
Enlivex Therapeutics Ltd.
ENLV
NASDAQ
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
1.24 USD
0.06 (4.84%)
About
ceo
Dr. Oren Hershkovitz Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.enlivex.comexchange
NASDAQ
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
CIK
0001596812
ISIN
IL0011319527
CUSIP
M4130Y106
Address
14 Einstein Street
Phone
972 8 662 3301
Country
IL
Employee
71
IPO Date
Jul 31, 2014
Key Executives
